CADL
Candel Therapeutics, Inc. NASDAQ Listed Jul 27, 2021$7.80
Mkt Cap $428.2M
52w Low $4.34
94.8% of range
52w High $7.99
50d MA $5.49
200d MA $5.57
P/E (TTM)
-9.0x
EV/EBITDA
-3.8x
P/B
6.6x
Debt/Equity
0.0x
ROE
-73.5%
P/FCF
-7.7x
RSI (14)
—
ATR (14)
—
Beta
-0.81
50d MA
$5.49
200d MA
$5.57
Avg Volume
1.4M
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
CIK (SEC)
Phone
617 916 5445
117 Kendrick Street · Needham, MA 02494 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.24 | -0.54 | -125.0% | 4.98 | +1.2% | -6.2% | +0.2% | +3.8% | +1.2% | -1.4% | — |
| Nov 13, 2025 | AMC | -0.17 | -0.21 | -23.5% | 4.61 | -1.7% | +0.7% | +2.6% | +0.2% | -4.1% | -4.1% | — |
| Aug 14, 2025 | AMC | -0.17 | -0.09 | +47.1% | 6.04 | +0.8% | +0.8% | -1.3% | -7.9% | -7.9% | -4.1% | — |
| May 13, 2025 | AMC | -0.24 | 0.13 | +154.2% | 5.40 | +1.1% | -1.1% | -5.4% | -0.9% | +5.6% | +9.4% | — |
| Mar 13, 2025 | AMC | -0.23 | -0.40 | -73.9% | 7.94 | +0.3% | +10.2% | +11.2% | +11.1% | +12.1% | +3.9% | — |
| Nov 14, 2024 | AMC | — | -0.33 | — | 4.30 | +1.2% | -11.6% | -7.9% | -7.2% | -7.4% | -3.7% | — |
| Aug 13, 2024 | AMC | — | -0.74 | — | 5.84 | -0.7% | -9.9% | -7.9% | -9.8% | -10.1% | -10.1% | — |
| May 14, 2024 | AMC | — | -0.28 | — | 10.70 | +1.2% | +30.8% | +18.7% | +7.5% | +12.0% | +14.7% | — |
| Mar 28, 2024 | AMC | -0.16 | -0.38 | -137.5% | 1.58 | +8.9% | +10.8% | +7.0% | +6.3% | +305.1% | +320.3% | — |
| Nov 9, 2023 | AMC | -0.19 | -0.29 | -52.6% | 0.87 | +3.4% | +3.8% | +4.6% | +6.9% | +12.3% | +18.4% | — |
| Aug 10, 2023 | AMC | -0.23 | -0.33 | -43.5% | 1.06 | +1.9% | +8.5% | +8.5% | +9.4% | +5.7% | +6.6% | — |
| May 11, 2023 | AMC | -0.35 | -0.30 | +14.3% | 1.72 | -4.1% | -9.9% | -7.0% | -8.1% | -9.3% | -0.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18 | Citigroup | Maintains | Buy → Buy | — | $5.17 | $5.22 | +1.0% | -2.5% | -5.0% | -3.9% | -3.5% | -7.0% |
| Mar 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.98 | $5.04 | +1.2% | -6.2% | +0.2% | +3.8% | +1.2% | -1.4% |
| Mar 13 | Citigroup | Maintains | Buy → Buy | — | $4.98 | $5.04 | +1.2% | -6.2% | +0.2% | +3.8% | +1.2% | -1.4% |
| Dec 8 | Stephens & Co. | Maintains | Overweight → Overweight | — | $5.33 | $5.42 | +1.7% | +2.3% | +6.2% | +8.8% | +21.4% | +19.1% |
| Nov 21 | Freedom Broker | Maintains | Buy → Buy | — | $4.42 | $4.44 | +0.5% | +2.9% | +2.5% | +1.1% | +4.5% | +7.9% |
| Nov 14 | Citigroup | Maintains | Buy → Buy | — | $4.61 | $4.53 | -1.7% | +0.7% | +2.6% | +0.2% | -4.1% | -4.1% |
| Sep 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.54 | $5.59 | +0.9% | -2.5% | -7.9% | +0.0% | -2.3% | +0.4% |
| Sep 3 | BofA Securities | Downgrade | Buy → Neutral | — | $5.86 | $5.44 | -7.2% | -12.8% | -16.6% | -14.7% | -13.0% | -15.2% |
| Apr 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.77 | $4.87 | +2.1% | +4.2% | +8.4% | +3.8% | -5.0% | -4.2% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.94 | $7.96 | +0.3% | +10.2% | +11.2% | +11.1% | +12.1% | +3.9% |
| Feb 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $8.39 | $8.89 | +6.0% | +1.0% | +2.5% | +7.0% | -5.7% | -6.1% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.39 | $8.89 | +6.0% | +1.0% | +2.5% | +7.0% | -5.7% | -6.1% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.60 | $6.73 | +2.0% | -1.1% | +50.9% | +32.6% | +30.8% | +33.3% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.80 | $3.96 | +4.2% | +4.2% | +5.0% | +4.7% | +8.9% | +32.6% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.90 | $0.92 | +1.8% | +0.7% | +3.0% | +8.2% | +14.1% | -0.3% |
| May 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.57 | $1.57 | +0.0% | +7.6% | +3.2% | -1.9% | -7.0% | -7.6% |
| May 15 | BMO Capital | Maintains | Outperform → Outperform | — | $1.55 | $1.56 | +0.6% | +3.2% | +1.9% | +0.6% | +10.3% | +1.3% |
| Mar 31 | Credit Suisse | Maintains | Outperform → Outperform | — | $1.38 | $1.40 | +1.3% | -2.4% | +2.0% | +1.3% | +2.7% | +0.5% |
| Dec 7 | Credit Suisse | Maintains | Outperform → Outperform | — | $1.67 | $1.66 | -0.6% | -7.8% | +13.8% | +25.1% | +38.3% | +28.1% |
| Dec 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.80 | $1.85 | +2.8% | +4.4% | +6.7% | -7.2% | -14.4% | +5.6% |
| Sep 2 | BMO Capital | Maintains | Outperform → Outperform | — | $3.50 | $3.36 | -4.0% | -6.6% | -4.0% | +0.0% | +12.6% | +16.6% |
| Mar 31 | BMO Capital | Maintains | Outperform → Outperform | — | $4.59 | $4.73 | +3.1% | +10.9% | +14.4% | +13.9% | +9.6% | +6.1% |
| Nov 19 | BMO Capital | Maintains | Outperform → Outperform | — | $10.70 | $10.99 | +2.7% | +1.6% | -8.4% | -6.2% | -3.6% | -8.6% |
| Aug 23 | Credit Suisse | Maintains | Outperform → Outperform | — | $6.30 | $6.80 | +7.9% | +25.9% | +24.0% | +21.0% | +24.4% | +27.0% |
| Aug 23 | Jefferies | Maintains | Buy → Buy | — | $6.30 | $6.80 | +7.9% | +25.9% | +24.0% | +21.0% | +24.4% | +27.0% |
| Aug 23 | UBS | Maintains | Buy → Buy | — | $6.30 | $6.80 | +7.9% | +25.9% | +24.0% | +21.0% | +24.4% | +27.0% |
No insider trades available.
8-K
Unknown — 8-K Filing
Candel Therapeutics secured $130 million in debt financing, extending its cash runway to advance cancer immunotherapy development, but increasing financial obligations that could dilute shareholders if clinical trials fail.
Mar 12
8-K
Candel Therapeutics, Inc. -- 8-K Filing
Candel Therapeutics raised approximately $93.5 million through a public offering to fund commercial launch activities for its CAN-2409 therapy, with potential proceeds reaching $107.6 million if underwriters exercise their full option.
Feb 23
8-K · 8.01
!! High
Candel Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
I need more details from the filing summary to provide meaningful analysis. The provided text appears incomplete and doesn't contain substantive information about Candel Therapeutics' material event or announcement.
Could you provide the actual content describing what the material event or announcement was?
Feb 19
Data updated apr 24, 2026 11:38pm
· Source: massive.com